Fig. 4.

Association of early IFN therapy with early recovery from COVID-19 depended on GC cumulative dose. a–c Cumulative incidence curves for hospital discharge among survivors receiving 40–120 mg (a), 120–320 mg (b), or >320 mg methylprednisolone-equivalent doses of GC in total during hospitalization. n = 32 for a, 48 (early IFN) and 29 (no early IFN) for b, 36 (early IFN) and 23 (no early IFN) for c. e, f Cumulative incidence curves for hospital discharge among survivors without (e) or with early IFN therapy (f). P-values were calculated by comparing all 4 curves. n = 87 (no GC), 32 (GC 40–120 mg), 29 (GC 121–320 mg), and 23 (GC > 320 mg) for e, 87 (no GC), 32 (GC 40–120 mg), 48 (GC 121–320 mg), and 36 (GC > 320 mg) for f